OCS logo

OCULIS HOLDING AG

OCSNASDAQ
🏆 #2886 by market capEarnings Nov 3 · PreUS Equity
——
Quote unavailable
🔔
Track OCS
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$482M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
35.2%
Healthy
💵FCF Margin
-27182.0%
Thin
⚖️P/S Ratio
1646.9x
Expensive
Otter Score
32
Weak
No chart data available for OCS.

Trading Snapshot

Day Range
—
52-Week Range
$7.11 – $34.48
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
61.6M
Next Earnings
2026-11-03

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-4.6
P/S Ratio
1646.9x
EPS (TTM)
$-1.30
Dividend Yield
0.00%
Dilution (1yr)
+33.9%
OCS logo

OCULIS HOLDING AG

OCS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$79M▲ +8.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$63M▲ +31.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
56.0M▲ +33.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$79M▲ +$53M YoY
StockOtter · stockotter.space

About OCULIS HOLDING AG

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
32/100

Analyst Ratings

ⓘ
Consensus
Buy
15 analysts
Strong Buy7
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.